Pulmonary Amyloidosis: Diverse Clinical and Histopathological Manifestations - A Series of Five Cases
DOI:
https://doi.org/10.21276/apalm.3683Keywords:
pulmonary amyloidosis, localized amyloidosis, systemic amyloidosis, congo red staining, immunohistochemistry, lung pathology, case series, amyloid subtypingAbstract
Pulmonary amyloidosis, a rare condition caused by the abnormal deposition of protein fibrils, most often the AL (light chain) type, within the lung, frequently presents a diagnostic challenge. Its clinical manifestations often resemble more prevalent lung diseases like cancer or infections. A crucial step is to differentiate between disease limited to the respiratory system and widespread systemic involvement, as this guides the appropriate treatment. This report provides a retrospective analysis of five histologically confirmed cases of pulmonary amyloidosis, detailing their presenting clinical features, radiological findings, microscopic tissue characteristics, immunohistochemical analysis, and results from systemic evaluations. Our patient group, comprising three males and two females aged between 38 and 67 years, presented with varied initial symptoms: three had lung masses, one exhibited pleural effusion with concurrent liver disease, and another was being treated for tuberculosis. Microscopic examination revealed discrete amyloid nodules in three cases, diffuse interstitial deposition in one, and a pleural based accumulation in another. Immunohistochemical studies confirmed AL-type amyloid in three cases, AA-type in one, while the specific amyloid type remained undetermined in a fifth case. A confirmed diagnosis of systemic amyloidosis was made in only one patient. In one instance, nodular pulmonary amyloidosis occurred alongside fungal colonization. Pulmonary amyloidosis often poses a diagnostic conundrum in lung pathology. While localized nodular forms generally follow a benign clinical course, diffuse patterns necessitate a thorough systemic evaluation, even when serological indicators are negative. Advanced techniques like mass spectrometry and extensive imaging are becoming more vital for accurate subtyping and informed treatment decisions.References
1. Gandham AK, Gayathri AR, Sundararajan L. Pulmonary amyloidosis: A case series. Lung India. 2019 May–Jun;36(3):229–232.
2. Moy LN, Mirza M, Moskal B, Asado N, Shah B, Bitran J, et al. Pulmonary AL amyloidosis: A review and update on treatment options. Ann Med Surg (Lond). 2022 Aug;80:104060.
3. Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev. 2017 Sep 6;26(145):170046.
4. Wadhera S, Swain RN, Jandial A, Sachdeva MU, Nada R, Malhotra P, et al. Diffuse alveolar-septal amyloidosis and paravertebral amyloidoma presenting as exertional desaturation. Indian J Hematol Blood Transfus. 2025 May 17.
5. Neacşu F, Vârban AŞ, Simion G, Şurghie R, Pătraşcu OM, Sajin M, et al. Lung cancer mimickers – a case series of seven patients and review of the literature. Rom J Morphol Embryol. 2021 Jul–Sep;62(3):697–704.
6. Riehani A, Soubani AO. The spectrum of pulmonary amyloidosis. Respir Med. 2023 Nov;218:107407.
7. Kratka K, Sistik P, Olivkova I, Kusnierova P, Svagera Z, Stejskal D. Mass spectrometry-based proteomics in clinical diagnosis of amyloidosis and multiple myeloma: A review (2012–2024). J Mass Spectrom. 2025 Mar;60(3):e5116.
8. Fisher B, Ikeji C, Brackney C, Dhupar R. Pulmonary amyloidosis presenting as recurrent pleural effusion and hemoptysis leading to pulmonary infarction and fatal cardiopulmonary arrest: a case report. Arch Surg Surg Educ. 2022;4:043.
9. Li F, Li J, Li Y, Shang D, Hou X, He Y, Li G. Imaging and clinical features of nodular pulmonary amyloidosis. J Thorac Imaging. 2025 Sep 1;40(5):e0830.
10. Chakraborty R, Bellofiore C, Basset M, Nuvolone M, Foli A, Merlini G, et al. PB2151: Clinical features and outcomes of diffuse pulmonary light chain amyloidosis: a rare presentation of systemic AL amyloidosis. HemaSphere. 2023 Aug 8;7(S3):e740260a.
11. Klotz SA, Sobonya RE, Lipke PN, Garcia-Sherman MC. Serum amyloid P component and systemic fungal infection: does it protect the host or is it a Trojan horse? Open Forum Infect Dis. 2016 Aug 3;3(3):ofw166.
12. Janssens I, Lambrecht BN, Van Braeckel E. Aspergillus and the lung. Semin Respir Crit Care Med. 2024 Feb;45(1):3–20.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Richa Bhartiya, Pallavi Mehra, Vishal Tayade, Navin K. Bariar, Mansi Karwa, Pritisha Choudhury

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
